Heartbeam, Inc.

Greetings and welcome to the HeartBeam second quarter 2022 financial results conference call. At this time, all participants will be in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject page 2 of 6 to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any provision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. We should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wires this afternoon at 4.01 p.m. Eastern Time and is available in the investor relations section of our company's website, heartbeam.com. Your hosts today are Bratislav Vybich, Chief Executive Officer and Founder, John Hunt, Chief Business Officer, and Rick Brownstein, Chief Financial Officer, who will present results of operations for the second quarter ended June 30, 2022. At this time, I'll turn the call over to Heartbeam Chief Executive Officer, Bratislav Vybich.

Thank you, operator, and good afternoon, everyone. I'm pleased to welcome you to today's second quarter 2022 financial results conference call. Our second quarter was highlighted by steady enhancement along our commercialization pathway, including the upcoming submission of our emerging department product, now called in Amy, to the FDA on or about August 15th. We continue to make progress in getting our second product, the telemedicine platform, now called AmyGo, prepared for FDA submission in Q4 of this year. In evaluating the database for the clinical validation of hard Amy product, we discovered a significant number of consecutive patients that fell into the category of an unstable a serial cardiac condition, patients with unstable angina may have subtle electrical changes brought on by ischemia without definitive injury to the cardiac tissue. Based on these findings, we expanded the patient population for the company's software product to include unstable angina as a diagnosis for analysis and provide access to wider patient population for our technology once we have clearance from the FDA. We have recently acquired the source code together with the perpetual royalty-free license for the hard-branded version of the FDA-listed Libmore Hello Plus platform, key components of our products. Moreover, This development will enable us to continue development of this powerful platform internally. We were privileged to welcome Ken Pearson to the role of Chief Technology Officer to lead overall technology strategy and development of the HeartBeam Aiming and HeartBeam Go platforms. Ken has over 25 years experience in the digital healthcare and cardiac device industries. Most recently, he founded a digital health company, Limor, where he served as chief technology officer. We were most honored during this quarter to be selected as the winner of the annual 2020 Cardiovascular Innovation Summit, recognizing our unique approach to heart attack detection. I would now like to turn the call over to John Hunt, our Chief Business Officer, to further discuss our products and commercialization plans.

John? John, you may be on mute, John.